reports
Moody's Ratings assigns P-3 rating to HCA Inc.'s commercial paper prog...
Moody's Ratings (Moody's) today assigned a Prime-3 (P-3) rating to the new backed senior unsecured commercial paper program of HCA Inc. ("HCA"). At the same time, we affirmed HCA's existing ratings including the Baa3 ratings of senior unsecured debentures/notes, backed senior unsecured notes and the...
Tenet Healthcare Corp: 2 directors
Two Directors at Tenet Healthcare Corp sold 8,574 shares at between 173.000USD and 173.160USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
- Dave Nicoski
- Ross LaDuke
RCKY ROCKY BRANDS
PZZA PAPA JOHN'S INTERNATIONAL INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MU MICRON TECHNOLOGY INC.
MSA MSA SAFETY INC.
MPC MARATHON PETROLEUM CORPORATION
MCHP MICROCHIP TECHNOLOGY INCORPORATED
KOP KOPPERS HOLDINGS INC.
GPC GENUINE PARTS COMPANY
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CVGW CALAVO GROWERS INC.
BEN FRANKLIN RESOURCES INC.
AAP ADVANCE AUTO PARTS INC.
MEG. MEG ENERGY CORP.
FSLR FIRST SOLAR INC.
KALU KAISER ALUMINUM CORPORATION
PVH PVH CORP.
NHC NATIONAL HEALTHCARE CORP.
ELF E.L.F. BEAUTY INC.
DK DELEK US HOLDINGS INC
SCPH SCPHARMACEUTICALS INC
MTW MANITOWOC COMPANY INC.
TTEC TTEC HOLDINGS INC.
ADNT ADIENT PLC
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
OCGN OCUGEN INC
ITOS ITEOS THERAPEUTICS
ETWO E2OPEN PARENT HOLDINGS INC (A)
PAX PATRIA INVESTMENTS
VAL VALARIS LTD
DINO HOLLYFRONTIER CORP
NE NOBLE CORP (NEW)
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
LRCX LAM RESEARCH CORPORATION
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Expecting a Test of All-Time Highs The market remains relentlessly strong, shrugging off the latest "bearish" headline regarding Moody's U.S. debt downgrade on Friday. This is exactly what we would expect to happen in a bull market, particularly during this "lockout rally," and helps confirm our bullish outlook. To recap, we have been short-term bullish since our 4/22/25 Compass -- when the SPX was testing 5100-5120 support -- but we upgraded our intermediate-term outlook to bullish as well, as...
HCA Healthcare Inc: 1 director
A director at HCA Healthcare Inc sold 15,698 shares at 369.325USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results an...
scPharmaceuticals Inc. Reports First Quarter 2025 Financial Results and Provides Business Update Generated net FUROSCIX® revenue of $11.8 million in the first quarter of 2025 Formally launched FUROSCIX in second approved indication, Chronic Kidney Disease, in April 2025 Autoinjector on track for sNDA submission in Q3 2025; designed to reduce treatment time from five hours to less than ten seconds Cash and cash equivalents of $57.5 million as of March 31, 2025 Investor conference call and webcast today, Wednesday, May 14th, at 4:30pm ET BURLINGTON, Mass., May 14, 2025 (GLOBE NEWSWIRE)...
scPharmaceuticals to Announce First Quarter 2025 Financial Results Aft...
scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025 Management to host conference call and webcast, after-market on May 14, 2025, at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first q...
scPharmaceuticals Announces Participation in Three Upcoming Investor C...
scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: We...
- Dave Nicoski
- Ross LaDuke
BKD BROOKDALE SENIOR LIVING INC.
STRL STERLING CONSTRUCTION COMPANY INC.
SLP SIMULATIONS PLUS
MKTX MARKETAXESS HOLDINGS INC.
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
HII HUMANA INC.
HCA HUNTINGTON INGALLS INDUSTRIES INC.
GD HCA HEALTHCARE INC
DLTR GENERAL DYNAMICS CORPORATION
DG DOLLAR TREE INC.
CVGW DOLLAR GENERAL CORPORATION
CNC CALAVO GROWERS INC.
CL CENTENE CORPORATION
CACI COLGATE-PALMOLIVE COMPANY
FDP CACI INTERNATIONAL INC CLASS A
SJW FRESH DEL MONTE PRODUCE INC.
LKO SJW GROUP
FIZZ LAKES OIL N.L.
CELH NATIONAL BEVERAGE CORP.
PAGS CELSIUS HOLDINGS INC.
STNE PAGSEGURO DIGITAL LTD
LHX STONECO
CERT L3HARRIS TECHNOLOGIES INC
MASS CERTARA
CTGO 908 DEVICES
NTST CONTANGO ORE INC.
YOU NETSTREIT CORP
HUM CLEAR SECURE INC
HAMILTON U.S. MID-CAP FINANCIALS ETF
Moody's Ratings affirms HCA Inc.'s Baa3 ratings; revises outlook to po...
Moody's Ratings (Moody's) affirmed the ratings of HCA Inc. ("HCA") including the Baa3 ratings of senior unsecured debentures/notes, backed senior unsecured notes and the senior unsecured bank credit facility. At the same time, we revised the outlook to positive from stable. The revision of outlook...
- Dave Nicoski
- Ross LaDuke
COP CONOCOPHILLIPS
SPTN SPARTANNASH CO
GE GENERAL ELECTRIC COMPANY
SLB.N SCHLUMBERGER NV
CNHI CNH INDUSTRIAL NV
WLDN WILLDAN GROUP
SIG SIGNET JEWELERS LIMITED
EVEREST RE GROUP LTD.
RDN RADIAN GROUP INC.
NSP INSPERITY INC.
NEU NEWMARKET CORPORATION
MOS MOSAIC COMPANY
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
LKQ LKQ CORPORATION
HOO HERBALIFE NUTRITION LTD.
HCA HCA HEALTHCARE INC
EEFT EURONET WORLDWIDE INC.
DVN DEVON ENERGY CORPORATION
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CTRE CARETRUST REIT INC
CROX CROCS INC.
BAX BAXTER INTERNATIONAL INC.
FDP FRESH DEL MONTE PRODUCE INC.
SJW SJW GROUP
EVTC EVERTEC INC.
POR PORTLAND GENERAL ELECTRIC COMPANY
YORW YORK WATER CO.
SEB SEABOARD CORP.
CELH CELSIUS HOLDINGS INC.
STNE STONECO
CMT COMPTON PETROLEUM CORP.
CNXC CONCENTRIX
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Finan...
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th,...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financ...
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 Management to host conference call and webcast, after-market on March 19, 2025, at 4:30 p.m. ET BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Appl...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025 BURLINGTON, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), ...
scPharmaceuticals Announces Participation in Two Upcoming Investor Con...
scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will present at the following upcoming investor conferences: 45th Annual TD Cowen Healthcare Conference: Fireside chat on Wednesday, March 5 at 11:10AM ET.Leerink Partners 2025 Global Healthcare Conference: Corporate pre...
Moody's Ratings assigns Baa3 rating to HCA's senior unsecured revolvin...
Moody's Ratings (Moodys) assigned a Baa3 rating to HCA Inc.'s ("HCA") new $8.0 billion senior unsecured revolving credit facility maturing in 2030. HCA intends to use the revolver for general corporate purposes. The new revolver replaces HCA's senior secured revolving credit facilities -- $4.5 billi...
Moody's Ratings assigns Baa3 rating to HCA's proposed senior unsecured...
Moody's Ratings (Moody's) assigned Baa3 ratings to HCA Inc.'s ("HCA") proposed offering of backed senior unsecured notes of up to $5.25 billion with various maturities. HCA intends to use the net proceeds from this offering for general corporate purposes including repayment of borrowings outstanding...
Moody's Ratings assigns Baa3 rating to HCA's proposed senior unsecured...
Moody's Ratings (Moodys) assigned Baa3 ratings to HCA Inc.'s ("HCA") proposed offering of backed senior unsecured notes of up to $5.25 billion with various maturities. HCA intends to use the net proceeds from this offering for general corporate purposes including repayment of borrowings outstanding ...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare...
scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET. A webcast of the presentation can be accessed or under “News & Events” in the Invest...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Fu...
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE N...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.